Call For Committee Applications Applications are open for AMCP’s 2022-23 committees. Learn more Close

Partnership Forums

AMCP holds various meetings, forums, symposia, summits and other gatherings of experts to discuss topics of importance to managed care pharmacy. This section contains proceedings and findings and other documents that result from these events. 

AMCP Partnership Forums bring together payers, pharmacies, integrated delivery system leaders, HEOR analysts, academics, providers, pharmaceutical manufacturers and various other health care stakeholders to discuss key issues facing managed care pharmacy and collaboratively help shape the changing health care landscape. The events are invitation only and are supported by our partners. The findings from the forums are shared with members via webinars and proceedings published in the Journal of Managed Care & Specialty Pharmacy.

Upcoming:

Digital Therapeutics 2.0

The role of digital therapies in preventing, managing, and treating medical conditions has evolved greatly in the past few years. They may be used independently or taken in tandem with other therapies to optimize clinical outcomes for patients.  Further, patients can self-manage these therapies or they can be managed under the direction of a clinician. As innovative therapies are introduced into the market, challenges with developing evidence-based coverage criteria and tracking utilization have been identified. This forum will outline the key barriers and develop solutions to support the appropriate use and coverage of digital therapeutics in the health care system. 

This forum will identify challenges and payer needs related to the evidence for digital therapeutics. The forum will explore the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.

Aug 31-Sep 1, 2021| Virtual Meeting

Addressing Evidence Gaps in the Expedited Approval Process: Payer Perspectives 

Drug development is expensive, time consuming and risky. To address these factors, clinical and regulatory experts in pharmaceutical companies design drug development programs and clinical trials with a focus on  meeting the FDA requirements. Especially with drugs approved via expedited  pathways, the payer's perspective typically takes a back seat to FDA approval criteria. Further, payer expectations for efficacy and safety, as well as population parameters, can differ from those established to meet FDA stipulations. However, meeting payers’ expectations is critical for patient access and commercial success. Payers increasingly demand demonstration of long-term value, especially for high investment medications or those with a high-risk safety profile. Despite the rigorous steps in the process of drug development, limitations exist due to the difference between FDA approval requirements and payer evidence needs. Participants will outline payer needs, barriers, and solutions for products approved through an expedited approval process regarding evidence for new drug products. 

This forum will identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants will identify potential solutions to address evidence gaps. 

Nov 18-19, 2021 | The Alexandrian Old Town , Alexandria, VA

WORKGROUP - Addressing Barriers to Value-based Payment Models in Integrated Delivery Networks

Collaborate with a group of key stakeholders to address how existing laws are impacting integrated delivery networks (IDNs) and pharmaceutical partnerships. Legal and regulatory requirements (e.g., the Anti-Kickback Statute and Medicaid best price rule) can limit the use of certain strategies that could potentially improve care coordination and patient outcomes. Successful implementation of value-based agreements in IDNs requires a range of complex capabilities. The workgroup will provide examples of real-world challenges and possible solutions that will inform and support efforts for legislative change.

WORKGROUP - Substance Use Disorder: A Focus on Prescription Drug Use 

Despite efforts to decrease the use of opioids, challenges remain.  AMCP created multiple advisory groups beginning in 2015 recognizing the widespread and devastating nature of the opioid crisis.  Over time, these groups addressed access to medications for treatment of substance use disorders and  developed a viewpoint document on the importance of co-prescribing naloxone. The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address  substance use disorder.